Recombinant human deoxyribonuclease I

Pharmaceutical Biotechnology: Fundamentals and Applications, Fourth Edition

Volumn , Issue , 2013, Pages 321-336

  Lazarus, Robert A ^a   Wagener, Jeffrey S ^b  

^a GENENTECH INC   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALS; METAL IONS; METALS; NUCLEIC ACIDS;

APOPTOTIC NUCLEASE; BOVINE DNASE I; DEOXYRIBONUCLEASE; DIVALENT METAL ION; EXTRACELLULAR; GASTROINTESTINAL TRACT; PAROTID GLANDS; SIGNAL SEQUENCE;

ENZYME ACTIVITY;

EID: 84947065879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6486-0_16     Document Type: Chapter

References (117)

1. Ago H, Oda M, Takahashi M, Tsuge H, Ochi S, Katunuma N, Miyano M, Sakurai J (2006) Structural basis of the sphingomyelin phosphodiesterase activity in neutral sphingomyelinase from Bacillus cereus. J Biol Chem 281: 16157-16167
2. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A (1992) Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 267: 1947-1951
3. Altunhan H, Annagür A, Pekcan S, Ors R, Koç H (2012) Comparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newborns. Pediatr Int 54: 131-136
4. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F (2011) The effect of dornase alfa on ventilation in homogeneity in patients with cystic fibrosis. Eur Respir J 37: 806-812
5. Andreeva A, Howorth D, Chandonia JM, Brenner SE, Hubbard TJ, Chothia C, Murzin AG (2008) Data growth and its impact on the SCOP database: new developments. Nucleic Acids Res 36: D419-25
6. Armstrong JB, White JC (1950) Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet 2: 739-742
7. Bakker EM, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas CJJCM, Hop WCJ, Assael BM, Merkus PJFM, Tiddens HAWM (2011) Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 38: 1328-1335
8. Baranovskii AG, Buneva VN, Nevinsky GA (2004) Human deoxyribonucleases. Biochemistry (Mosc) 69: 587-601
9. Bataillon V, Lhermitte M, Lafitte JJ, Pommery J, Roussel P (1992) The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases. J Antimicrob Chemother 29: 499-508
10. Boogaard R, de Jongste JC, Merkus PJ (2007a) Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature. Pediatr Pulmonol 42: 989-1001
11. Boogaard R, Hulsmann AR, van Veen L, Vaessen-Verberne AA, Yap YN, Sprij AJ, Brinkhorst G, Sibbles B, Hendriks T, Feith SW, Lincke CR, Brandsma AE, Brand PL, Hop WC, de Hoog M, Merkus PJ (2007b) Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis. Chest 131: 788-795
12. Campbell VW, Jackson DA (1980) The effect of divalent cations on the mode of action of DNase I. The initial reaction products produced from covalently closed circular DNA. J Biol Chem 255: 3726-3735
13. Carpenter EP, Corbett A, Thomson H, Adacha J, Jensen K, Bergeron J, Kasampalidis I, Exley R, Winterbotham M, Tang C, Baldwin GS, Freemont P (2007) AP endonuclease paralogues with distinct activities in DNA repair and bacterial pathogenesis. EMBO J 26: 1363-1372
14. Chen WJ, Liao TH (2006) Structure and function of bovine pancreatic deoxyribonuclease I. Protein Pept Lett 13: 447-453
15. Chernick WS, Barbero GJ, Eichel HJ (1961) In vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics 27: 589-596
16. Cimmino M, Nardone M, Cavaliere M, Plantulli A, Sepe A, Esposito V, Mazzarella G, Raia V (2005) Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. Arch Otolaryngol Head Neck Surg 131: 1097-1101
17. Cipolla D, Gonda I, Shire SJ (1994) Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers. Pharm Res 11: 491-498
18. Dasgupta B, King M (1996) Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol 22: 161-166
19. Davis JC Jr, Manzi S, Yarboro C, Rairie J, McInnes I, Averthelyi D, Sinicropi D, Hale VG, Balow J, Austin H, Boumpas DT, Klippel JH (1999) Recombinant human DNase I (rhDNase) in patients with lupus nephritis. Lupus 8: 68-76
20. Davoodian K, Ritchings BW, Ramphal R, Bubb MR (1997) Gelsolin activates DNase I in vitro and cystic fibrosis sputum. Biochemistry 36: 9637-9641
21. Desai M, Weller PH, Spencer DA (1995) Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome. Pediatr Pulmonol 20: 307-308
22. Dilmen U, Karagol BS, Oguz SS (2011) Nebulized hypertonic saline and recombinant human DNase in the treatment of pulmonary atelectasis in newborns. Pediatr Int 53: 328-331
23. Dlakic M (2000) Functionally unrelated signalling proteins contain a fold similar to Mg 2+-dependent endonucleases. Trends Biochem Sci 25: 272-273
24. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, Wilmott RW, Wohl ME, Fuchs HJ, Christiansen DH, Smith AL (1997) Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 131: 118-124
25. El Abiad NM, Clifton S, Nasr SZ (2007) Long-term use of nebulized human recombinant DNase I in two siblings with primary ciliary dyskinesia. Respir Med 101: 2224-2226
26. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240
27. Evans CJ, Aguilera RJ (2003) DNase II: genes, enzymes and function. Gene 322: 1-15
28. Fedakar A, Aydogdu C, Fedakar A, Ugurlucan M, Bolu S, Iskender M (2012) Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns. Ann Saudi Med 32: 131-136
29. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176: 957-969
30. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331: 637-642
31. Geller DE, Eigen H, Fiel SB, Clark A, Lamarre AP, Johnson CA, Konstan MW (1998) Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol 25: 83-87
32. Gonda I (1990) Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. Crit Rev Ther Drug Carrier Syst 6: 273-313
33. Green JD (1994) Pharmaco-toxicological expert report Pulmozyme rhDNase Genentech, Inc. Hum Exp Toxicol 13: S1-S42
34. Gueroult M, Picot D, Abi-Ghanem J, Hartmann B, Baaden M (2010) How cations can assist DNase I in DNA binding and hydrolysis. PLoS Comput Biol 6: e1001000
35. Guggino WB, Stanton BA (2006) New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 7: 426-436
36. Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005) DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care 9: R351-R356
37. Hitchcock SE, Carisson L, Lindberg U (1976) Depolymerization of F-actin by deoxyribonuclease I. Cell 7: 531-542
38. Horton NC (2008) DNA nucleases. In: Rice PA, Correll CC (eds) Protein-nucleic acid interactions: structural biology. Royal Society of Chemistry Publishing, Cambridge, pp 333-363
39. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG (1992) A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 326: 812-815
40. Jubin V, Ranque S, Le bel NS, Sarles J, Dubus J-C (2010) Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 45: 764-771
41. Kabsch W, Mannherz HG, Suck D, Pai EF, Holmes KC (1990) Atomic structure of the actin: DNase I complex. Nature 347: 37-44
42. Kaplan JB, LoVetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S, Izano EA (2012) Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in Staphylococci. J Antibiot (Tokyo) 65: 73-77
43. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073-1080
44. King M, Dasgupta B, Tomkiewicz RP, Brown NE (1997) Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 156: 173-177
45. Kominato Y, Ueki M, Iida R, Kawai Y, Nakajima T, Makita C, Itoi M, Tajima Y, Kishi K, Yasuda T (2006) Characterization of human deoxyribonuclease I gene (DNASE1) promoters reveals the utilization of two transcription-starting exons and the involvement of Sp1 in its transcriptional regulation. FEBS J 273: 3094-3105
46. Konstan MW, Ratjen F (2012) Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 11: 78-83
47. Konstan MW, Byard PJ, Hoppel CL, Davis PB (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332: 848-854
48. Konstan MW, Schluchter MD, Xue W, Davis PB (2007) Clinical use of Ibuprofen is associated with slower FEV 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176: 1084-1089
49. Konstan MW, VanDevanter DR, Rasouliyan L, Pasta DJ, Yegin A, Morgan WJ, Wagener JS (2010) Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 45: 1167-1172
50. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, Morgan WJ (2011) Clinical use of dornase alfa is associated with a slower rate of FEV 1 decline in cystic fibrosis. Pediatr Pulmonol 46: 545-553
51. Lachmann PJ (2003) Lupus and desoxyribonuclease. Lupus 12: 202-206
52. Laskowski M Sr (1971) Deoxyribonuclease I. In: Boyer PD (ed) The enzymes, vol 4, 3rd edn. Academic, New York, pp 289-311
53. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ (1996) Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 153: 752-760
54. Lazarides E, Lindberg U (1974) Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci USA 71: 4742-4746
55. Lazarus RA (2002) Human deoxyribonucleases. In: Creighton TE (ed) Wiley encyclopedia of molecular medicine. Wiley, New York, pp 1025-1028
56. Lieberman J (1962) Enzymatic dissolution of pulmonary secretions. An in vitro study of sputum from patients with cystic fibrosis of pancreas. Am J Dis Child 104: 342-348
57. Lieberman J (1968) Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA 205: 312-313
58. MacKinnon R, Wheeler KI, Sokol J (2011) Endotracheal DNase for atelectasis in ventilated neonates. J Perinatol 31: 799-801
59. Mainz JG, Schiller I, Ritschel C, Mentzel H-J, Riethmuller J, Koitschev A, Schneider G, Beck JF, Wiedemann B (2011) Sinonasal inhalation of dornase alfa in CF: a doubleblind placebo-controlled cross-over pilot trial. Auris Nasus Larynx 38: 220-227
60. Matthews LW, Specter S, Lemm J, Potter JL (1963) The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am Rev Respir Dis 88: 119-204
61. McCoy K, Hamilton S, Johnson C (1996) Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 110: 889-895
62. Mohler M, Cook J, Lewis D, Moore J, Sinicropi D, Championsmith A, Ferraiolo B, Mordenti J (1993) Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug Metab Dispos 21: 71-75
63. Mol CD, Izumi T, Mitra S, Tainer JA (2000) DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination. Nature 403: 451-456
64. Moore S (1981) Pancreatic DNase. In: Boyer PD (ed) The enzymes, vol 14, 3rd edn. Academic, New York, pp 281-296
65. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S (1999) Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U. S. and Canada. Pediatr Pulmonol 28: 231-241
66. Nasr SZ, Strouse PJ, Soskolne E, Maxvold NJ, Garver KA, Rubin BK, Moler FW (2001) Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 120: 203-208
67. O'Donnell AE, Barker AF, Ilowite JS, Fick RB (1998) Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 113: 1329-1334
68. Pan CQ, Lazarus RA (1997) Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism. Biochemistry 36: 6624-6632
69. Pan CQ, Lazarus RA (1999) Ca 2+-dependent activity of human DNase I and its hyperactive variants. Protein Sci 8: 1780-1788
70. Pan CQ, Ulmer JS, Herzka A, Lazarus RA (1998a) Mutational analysis of human DNase I at the DNA binding interface: implications for DNA recognition, catalysis, and metal ion dependence. Protein Sci 7: 628-636
71. Pan CQ, Dodge TH, Baker DL, Prince WS, Sinicropi DV, Lazarus RA (1998b) Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus. J Biol Chem 273: 18374-18381
72. Pan CQ, Sinicropi DV, Lazarus RA (2001) Engineered properties and assays for human DNase I mutants. Methods Mol Biol 160: 309-321
73. Parsiegla G, Noguere C, Santell L, Lazarus RA, Bourne Y (2012) The structure of human DNase I bound to magnesium and phosphate ions points to a catalytic mechanism common to members of the DNase I-like superfamily. Biochemistry 51: 10250-10258
74. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Döring G, van Koningsbruggen S, Wahn U, Ratjen F (2004) Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 169: 719-725
75. Potter JL, Specter S, Matthews LW, Lemm J (1969) Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis bronchiectasis and laryngectomy. Am Rev Respir Dis 99: 909-915
76. Prince WS, Baker DL, Dodge AH, Ahmed AE, Chestnut RW, Sinicropi DV (1998) Pharmacodynamics of recombinant human DNase I in serum. Clin Exp Immunol 113: 289-296
77. Puterman AS, Weinberg EG (1997) rhDNase in acute asthma. Pediatr Pulmonol 23: 316-317
78. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW (2001) A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139: 813-820
79. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, Bentley A, Kahan BC, Wrightson JM, Davies HE, Hooper CE, Lee YC, Hedley EL, Crosthwaite N, Choo L, Helm EJ, Gleeson FV, Nunn AJ, Davies RJ (2011) Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 365: 518-526
80. Ramphal R, Lhermitte M, Filliat M, Roussel P (1988) The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 22: 483-490
81. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, Wilmott RW, Wohl ME, Meyerson LJ, Shak S, Fuchs H, Smith AL (1993) Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 148: 145-151
82. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340: 23-30
83. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group (2011) A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. New Engl J Med 365: 1663-1672
84. Raskin P (1968) Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 98: 697-698
85. Raynor EM, Butler A, Guill M, Bent JP 3rd (2000) Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis. Arch Otolaryngol Head Neck Surg 126: 581-583
86. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ (2008) Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 153: 746-751
87. Riethmueller J, Borth-Bruhns T, Kumpf M, Vonthein R, Wiskirchen J, Stern M, Hofbeck M, Baden W (2006) Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol 41: 61-66
88. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui LC (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073
89. Robinson M, Hemming AL, Moriarty C, Eberl S, Bye PT (2000) Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol 30: 16-24
90. Rozov T, de Oliveira VZ, Santana MA, Adde FV, Mendes RH, Paschoal IA, Reis FJC, Higa LYS, de Castro Toledo Jr AC, Pahl M (2010) Dornase alfa improves the healthrelated quality of life among Brazilian patients with cystic fibrosis-a one-year prospective study. Pediatr Pulmonol 45: 874-882
91. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC (2005) Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 172: 1008-1012
92. Sanders NN, Franckx H, De Boeck K, Haustraete J, De Smedt SC, Demeester J (2006) Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax 61: 962-968
93. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L (2012) Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 47: 44-52
94. Scherer T, Geller DE, Owyang L, Tservistas M, Keller M, Boden N, Kesser KC, Shire SJ (2011) A technical feasibility study of dornase alfa delivery with eFlow vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci 100: 98-109
95. Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, Johnson CA, Light MC, Scott SF, Tullis DE, De Vault A, Wohl ME, Hodson ME (1995) Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 8: 954-958
96. Shak S (1995) Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 107: 65S-70S
97. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL (1990) Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 87: 9188-9192
98. Shiokawa D, Tanuma S (2001) Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry 40: 143-152
99. Shire SJ (1996) Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme, (dornase alfa)]. In: Pearlman R, Wang YJ (eds) Pharmaceutical biotechnology: formulation, characterization and stability of protein drugs, vol 9. Plenum Press, New York, pp 393-426
100. Silverman RA, Foley F, Dalipi R, Kline M, Lesser M (2012) The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study. Respir Med 106: 1096-1102
101. Simpson G, Roomes D, Reeves B (2003) Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 58: 365-366
102. Sinicropi DV, Lazarus RA (2001) Assays for human DNase I activity in biological matrices. Methods Mol Biol 160: 325-333
103. Sinicropi DV, Prince WS, Lofgren JA, Williams M, Lucas M, DeVault A (1994a) Sputum pharmacodynamics and pharmacokinetics of recombinant human DNase I in cystic fibrosis. Am J Respir Crit Care Med 149: A671
104. Sinicropi D, Baker DL, Prince WS, Shiffer K, Shak S (1994b) Colorimetric determination of DNase I activity with a DNA-methyl green substrate. Anal Biochem 222: 351-358
105. Suck D (1994) DNA recognition by DNase I. J Mol Recognit 7: 65-70
106. Suri R (2005) The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. BioDrugs 19: 135-144
107. ten Berge M, Brinkhorst G, Kroon AA, de Jongste JC (1999) DNase treatment in primary ciliary dyskinesia-assessment by nocturnal pulse oximetry. Pediatr Pulmonol 27: 59-61
108. Ulmer JS, Herzka A, Toy KJ, Baker DL, Dodge AH, Sinicropi D, Shak S, Lazarus RA (1996) Engineering actin-resistant human DNase I for treatment of cystic fibrosis. Proc Natl Acad Sci USA 93: 8225-8229
109. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP (1994) Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263: 969-971
110. Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC (1998) Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. J Pediatr 133: 486-491
111. Wang H, Morita M, Yang X, Suzuki T, Yang W, Wang J, Ito K, Wang Q, Zhao C, Bartlam M, Yamamoto T, Rao Z (2010) Crystal structure of the human CNOT6L nuclease domain reveals strict poly(A) substrate specificity. EMBO J 29: 2566-2576
112. Widlak P, Garrard WT (2005) Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 94: 1078-1087
113. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ (1996) Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 154: 413-417
114. Wilmott RW, Amin RS, Colin AA, DeVault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, Moss R, Nash ML, Jue CP, Regelmann W, Stokes DC, Fuchs HJ (1996) Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 153: 1914-1917
115. Wolf E, Frenz J, Suck D (1995) Structure of human pancreatic DNase I at 2. 2 Å resolution. Protein Eng 8: 79
116. Yang W (2011) Nucleases: diversity of structure, function and mechanism. Q Rev Biophys 44: 1-93
117. Zahm JM, Girod de Bentzmann S, Deneuville E, Perrot-Minnot C, Dabadie A, Pennaforte F, Roussey M, Shak S, Puchelle E (1995) Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur Respir J 8: 381-386